Table 1. PI-RADS scores version 2.0 and 2.1 for both readers and the number of detected prostate cancers (PCa) and clinically significant prostate cancers (csPCa).
| Reader 1 | Reader 2 | ||||||
|---|---|---|---|---|---|---|---|
| PI-RADS 2.0 | N (%) | # PCa (%) | # csPCa (%) | N (%) | # PCa (%) | # csPCa (%) | |
| 1 | 0 (0%) | 0/0 (0%) | 0/0 (0%) | 3 (1.31%) | 1/3 (33.33%) | 0/3 (0%) | |
| 2 | 79 (34.50%) | 18/79 (22.78%) | 9/79 (11.39%) | 53 (23.14%) | 18/53 (33.96%) | 14/53 (26.42%) | |
| 3 | 25 (10.92%) | 13/25 (52.00%) | 8/25 (32.00%) | 43 (18.78%) | 21/43 (48.84%) | 15/43 (34.88%) | |
| 4 | 91 (39.74%) | 83/91 (91.21%) | 72/91 (79.12%) | 90 (39.30%) | 71/90 (78.89%) | 59/90 (65.56%) | |
| 5 | 34 (14.85%) | 34/34 (100%) | 33/34 (97.06%) | 40 (17.47%) | 37/40 (92.50%) | 34/40 (85.00%) | |
| PI-RADS 2.1 | 1 | 34 (14.85%) | 6/34 (17.65%) | 2/34 (5.88%) | 8 (3.49%) | 2/8 (25%) | 1/8 (12.50%) |
| 2 | 45 (19.65%) | 12/45 (26.67%) | 7/45 (15.56%) | 45 (19.65%) | 16/45 (35.56%) | 12/45 (26.67%) | |
| 3 | 25 (10.92%) | 13/25 (52.00%) | 8/25 (32.00%) | 46 (20.09%) | 22/46 (47.83%) | 16/46 (34.78%) | |
| 4 | 91 (39.74%) | 83/91 (91.21%) | 72/91 (79.12%) | 90 (39.30%) | 71/90 (78.89%) | 59/90 (65.56%) | |
| 5 | 34 (14.85%) | 34/34 (100%) | 33/34 (97.06%) | 40 (17.47%) | 37/40 (92.50%) | 34/40 (85.00%) | |